Lifecore Biomedical Return on Equity

Lifecore Biomedical (LNDC) currently reports a ROE of 106.28%. That is above the Materials sector average of 10.8%. Use the charts on this page to explore Lifecore Biomedical's ROE history and peer comparisons.

Lifecore Biomedical's ROE of 106.28% is higher than the Materials sector average of 10.8%. That is roughly 883.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Lifecore Biomedical's current 106.28% should be judged against Materials norms (sector average: 10.8%) and against LNDC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 106.28%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Materials average is 10.8%. From there, open related valuation or income-statement pages for Lifecore Biomedical, and consider following LNDC for alerts when major investors trade the stock.

Lifecore Biomedical is classified in the Materials sector. On ROE, it currently shows 106.28% versus a sector average near 10.8%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Materials are usually more informative than comparing LNDC with unrelated industries.